Hematuria in IgAN: Marker, Mediator, or Both? Authors: Hiroki Nishiwaki Published: 2026 See Clinical Research on Article 106653 Hematuria is one of the most characteristic clinical manifestations of IgA nephropathy (IgAN), yet its prognostic significance has remained controversial for decades. In the article by Tang et al.,1 the authors provide important new evidence supporting the clinical relevance of persistent hematuria by applying marginal structural models to a large longitudinal cohort of 1771 patients with biopsy-proven IgAN. Their study demonstrates that although baseline hematuria was not associated with kidney disease progression, sustained time-updated hematuria of ≥ 100 red blood cells/μl was independently associated with a significantly increased risk of a composite kidney outcome. These findings represent an important step toward redefining hematuria as a dynamic risk marker in IgAN. The strengths of the study deserve emphasis. Hematuria is inherently variable over time and strongly influenced by disease activity, kidney function, proteinuria, and treatment exposure. Conventional regression approaches are often inadequate in such settings because time-dependent confounders may themselves be affected by previous exposure. By using marginal structural models, the authors addressed this methodological challenge and estimated the association between persistent hematuria and renal outcomes while accounting for evolving clinical parameters.2 Their findings are therefore more robust than previous analyses relying solely on baseline or time-averaged measurements. The study also reinforces a growing body of evidence suggesting that remission of hematuria carries prognostic information.3,4 Notably, the adverse association of persistent hematuria was most evident among patients with reduced baseline estimated glomerular filtration rate or persistent proteinuria, highlighting the possibility that hematuria identifies a subgroup with ongoing disease activity despite standard therapy. Yet, beyond its clinical message, this study raises a more fundamental question— where does hematuria reside within the pathogenic pathway of IgAN?5, 6, 7 One interpretation is that hematuria is a direct mediator of kidney injury. Experimental studies suggest that erythrocytes traversing a damaged glomerular filtration barrier release hemoglobin and iron, inducing oxidative stress, tubular toxicity, and interstitial inflammation. Under this model, persistent hematuria contributes directly to progressive nephron loss, and reducing hematuria would be expected to improve renal outcomes. An alternative interpretation is that hematuria is primarily a marker of active glomerular inflammation. Aberrant IgA-containing immune complexes, complement activation, and inflammatory injury may simultaneously generate hematuria, proteinuria, and declining kidney function. In this framework, hematuria reflects the underlying disease process rather than acting as an independent driver. Reduction in hematuria would therefore indicate successful suppression of disease activity rather than serving as a causal therapeutic target itself. The distinction is not merely conceptual. It directly influences how we interpret the time-dependent analyses performed in this study. Proteinuria and estimated glomerular filtration rate were treated as time-varying confounders within the marginal structural models framework. However, these variables may also lie along the biological pathway linking glomerular injury to kidney failure. Consequently, the estimated effect of hematuria may represent only part of a more complex causal network. Whether proteinuria precedes hematuria, follows hematuria, or evolves in parallel from a common inflammatory process remains uncertain. The significant interactions observed with baseline proteinuria and estimated glomerular filtration rate are particularly intriguing in this regard. The stronger association between persistent hematuria and adverse outcomes among patients with impaired kidney function may suggest heightened susceptibility to hematuria-mediated injury. Equally plausible, however, is the possibility that persistent hematuria simply identifies patients with more advanced and active disease. Distinguishing these explanations will require analytical approaches capable of explicitly modeling causal pathways and mediation effects over time. Therefore, the major contribution of this study may extend beyond establishing hematuria as a prognostic marker. By demonstrating the importance of longitudinally updated hematuria and employing modern causal inference methodology, the authors provide a framework for future investigations into the temporal relationships among hematuria, proteinuria, kidney function decline, and therapeutic response. As novel disease-specific therapies targeting complement activation, A proliferation-inducing ligand and B cell-activating factor pathways increasingly induce both proteinuria reduction and hematuria remission; therefore understanding the causal role of hematuria will become even more important.7 Future studies should seek not only to determine whether hematuria predicts outcome, but also to clarify whether it represents a mediator of disease progression, a marker of persistent inflammation, or both. In this respect, the present study marks an important milestone. It strengthens the clinical significance of persistent hematuria in IgAN while simultaneously encouraging a deeper exploration of the time-dependent mechanisms that connect hematuria, proteinuria, kidney function decline, and long-term renal outcomes. Disclosure The author declared no competing interests. References